1085P Health-related quality of life in stage III melanoma patients treated with neoadjuvant ipilimumab and nivolumab followed by index lymph node excision only versus therapeutic lymph node dissection: 24-week results of the PRADO trial

N.M.J Van Den Heuvel,K.H Blommers,A.C.J Van Akkooi,E Kapiteijn,K.P.M Suijkerbuijk,Thomas E Pennington ,Lonneke Van De Poll-Franse ,Georgina V Long ,Alexander M Menzies ,Andrew J Spillane ,Robyn P.m Saw ,Gap Hospers ,Christian U Blank ,Michel W.j.m Wouters ,Irene L M Reijers ,Judith M Versluis ,Elisa A Rozeman ,Katarzyna Jóźwiak ,Astrid A.m Van Der Veldt ,Annelies H Boekhout

doi:10.1016/j.annonc.2020.08.1209

1085P Health-related quality of life in stage III melanoma patients treated with neoadjuvant ipilimumab and nivolumab followed by index lymph node excision only versus therapeutic lymph node dissection: 24-week results of the PRADO trial

N.M.J Van Den Heuvel, K.H Blommers + Show 18 more

Open Access

https://doi.org/10.1016/j.annonc.2020.08.1209

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Sep 1, 2020
Citations: 2	License type: publisher-specific-oa

Affiliation: Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Leiden University Medical Center, University Medical Center Utrecht, Melanoma Institute Australia, University Medical Center Groningen, Erasmus MC

#Neoadjuvant Ipilimumab #Neoadjuvant Nivolumab + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

1085P Health-related quality of life in stage III melanoma patients treated with neoadjuvant ipilimumab and nivolumab followed by index lymph node excision only versus therapeutic lymph node dissection: 24-week results of the PRADO trial

Full Text